- Home
- IMCR vs OCUL Comparison
IMCR vs OCUL Comparison
Compare IMCR & OCUL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCR
- OCUL
- Stock Information
- Founded
- IMCR 2008
- OCUL 2006
- Country
- IMCR United Kingdom
- OCUL United States
- Employees
- IMCR N/A
- OCUL N/A
- Industry
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- OCUL Biotechnology: Pharmaceutical Preparations
- Sector
- IMCR Health Care
- OCUL Health Care
- Exchange
- IMCR Nasdaq
- OCUL Nasdaq
- Market Cap
- IMCR 1.4B
- OCUL 1.2B
- IPO Year
- IMCR 2021
- OCUL 2014
- Fundamental
- Price
- IMCR $29.58
- OCUL $7.58
- Analyst Decision
- IMCR Buy
- OCUL Strong Buy
- Analyst Count
- IMCR 12
- OCUL 9
- Target Price
- IMCR $63.00
- OCUL $16.22
- AVG Volume (30 Days)
- IMCR 372.8K
- OCUL 1.8M
- Earning Date
- IMCR 05-07-2025
- OCUL 03-03-2025
- Dividend Yield
- IMCR N/A
- OCUL N/A
- EPS Growth
- IMCR N/A
- OCUL N/A
- EPS
- IMCR N/A
- OCUL N/A
- Revenue
- IMCR $310,202,000.00
- OCUL $63,723,000.00
- Revenue This Year
- IMCR $18.97
- OCUL $14.02
- Revenue Next Year
- IMCR $8.43
- OCUL $15.47
- P/E Ratio
- IMCR N/A
- OCUL N/A
- Revenue Growth
- IMCR 24.36
- OCUL 9.03
- 52 Week Low
- IMCR $27.19
- OCUL $4.06
- 52 Week High
- IMCR $66.00
- OCUL $11.78
- Technical
- Relative Strength Index (RSI)
- IMCR 49.95
- OCUL 50.08
- Support Level
- IMCR $28.92
- OCUL $7.36
- Resistance Level
- IMCR $30.04
- OCUL $8.04
- Average True Range (ATR)
- IMCR 1.49
- OCUL 0.48
- MACD
- IMCR 0.10
- OCUL 0.01
- Stochastic Oscillator
- IMCR 53.71
- OCUL 18.29
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
About OCUL Ocular Therapeutix Inc.
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.